File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer

TitleA tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer
Authors
Wang, YanZhang, ChenXiao, MengGanesan, KumarGao, FeiLiu, QingqingYe, ZhenSui, YueZhang, FengWei, KunhuaWu, YaobinWu, JianminDu, BingXu, CongLi, YanLi, PengZhang, JinmingChen, Jianping
KeywordsBioavailability
Isoliquiritigenin
Safe therapeutic strategy
Triple-negative breast cancer
Zein-phosphatidylcholine hybrid nanoparticles
Issue Date10-Jan-2023
PublisherElsevier
Citation
Journal of Drug Delivery Science and Technology, 2023, v. 79 How to Cite?
DOI: http://dx.doi.org/10.1016/j.jddst.2022.103922
Abstract

Treatment of aggressive triple-negative breast cancer (TNBC) is still challenging. Isoliquiritigenin (ISL) is a water-insoluble bioactive compound possessing high anti-TNBC capacity with less toxicity. The present study aimed to develop a safe and effective oral drug delivery system to improve the oral efficacy of ISL for TNBC therapeutics. ISL-loaded zein phosphatidylcholine hybrid nanoparticles (ISL@ZLH NPs) were constructed by a one-step solvent evaporation method. Optimization and characterization of ISL@ZLH NPs were performed. Cellular uptake in vitro and biodistribution of ZLH NPs in vivo were investigated. The pharmacokinetics of ISL@ZLH NPs in terms of ISL content in the plasma, organs, and tumor tissues were validated, and the anti-TNBC efficacy was evaluated. Encapsulation efficiency (96.75 ± 1.41%) and drug loading efficiency (6.56 ± 0.83%) were found in ISL@ZLH NPs. ISL@ZLH NPs were able to enhance the absorption of ISL in the tumor sites. Moreover, the upregulation of p27 and downregulation of EGFR and CDK4 were observed in ISL@ZLH NPs treated tumors. Collectively, oral intake of ISL@ZLH NPs would be translated into a potential clinical therapy strategy against TNBC.


Persistent Identifierhttp://hdl.handle.net/10722/339100
ISSN
1773-2247
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 0.719
ISI Accession Number ID
WOS:000897066800001

 

DC FieldValueLanguage
dc.contributor.authorWang, Yan-
dc.contributor.authorZhang, Chen-
dc.contributor.authorXiao, Meng-
dc.contributor.authorGanesan, Kumar-
dc.contributor.authorGao, Fei-
dc.contributor.authorLiu, Qingqing-
dc.contributor.authorYe, Zhen-
dc.contributor.authorSui, Yue-
dc.contributor.authorZhang, Feng-
dc.contributor.authorWei, Kunhua-
dc.contributor.authorWu, Yaobin-
dc.contributor.authorWu, Jianmin-
dc.contributor.authorDu, Bing-
dc.contributor.authorXu, Cong-
dc.contributor.authorLi, Yan-
dc.contributor.authorLi, Peng-
dc.contributor.authorZhang, Jinming-
dc.contributor.authorChen, Jianping-
dc.date.accessioned2024-03-11T10:33:54Z-
dc.date.available2024-03-11T10:33:54Z-
dc.date.issued2023-01-10-
dc.identifier.citationJournal of Drug Delivery Science and Technology, 2023, v. 79-
dc.identifier.issn1773-2247-
dc.identifier.urihttp://hdl.handle.net/10722/339100-
dc.description.abstract<p>Treatment of aggressive triple-negative breast cancer (TNBC) is still challenging. <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/isoliquiritigenin" title="Learn more about Isoliquiritigenin from ScienceDirect's AI-generated Topic Pages">Isoliquiritigenin</a> (ISL) is a water-insoluble bioactive compound possessing high anti-TNBC capacity with less toxicity. The present study aimed to develop a safe and effective oral <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/drug-delivery-system" title="Learn more about drug delivery system from ScienceDirect's AI-generated Topic Pages">drug delivery system</a> to improve the oral efficacy of ISL for TNBC therapeutics. ISL-loaded <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/zein" title="Learn more about zein from ScienceDirect's AI-generated Topic Pages">zein</a> <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/egg-lecithin" title="Learn more about phosphatidylcholine from ScienceDirect's AI-generated Topic Pages">phosphatidylcholine</a> hybrid <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/nanoparticle" title="Learn more about nanoparticles from ScienceDirect's AI-generated Topic Pages">nanoparticles</a> (ISL@ZLH NPs) were constructed by a one-step solvent evaporation method. Optimization and characterization of ISL@ZLH NPs were performed. Cellular uptake in vitro and <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/biodistribution" title="Learn more about biodistribution from ScienceDirect's AI-generated Topic Pages">biodistribution</a> of ZLH NPs in vivo were investigated. The <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pharmacokinetics" title="Learn more about pharmacokinetics from ScienceDirect's AI-generated Topic Pages">pharmacokinetics</a> of ISL@ZLH NPs in terms of ISL content in the plasma, organs, and tumor tissues were validated, and the anti-TNBC efficacy was evaluated. Encapsulation efficiency (96.75 ± 1.41%) and drug loading efficiency (6.56 ± 0.83%) were found in ISL@ZLH NPs. ISL@ZLH NPs were able to enhance the absorption of ISL in the tumor sites. Moreover, the upregulation of p27 and downregulation of EGFR and CDK4 were observed in ISL@ZLH NPs treated tumors. Collectively, oral intake of ISL@ZLH NPs would be translated into a potential clinical therapy strategy against TNBC.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofJournal of Drug Delivery Science and Technology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBioavailability-
dc.subjectIsoliquiritigenin-
dc.subjectSafe therapeutic strategy-
dc.subjectTriple-negative breast cancer-
dc.subjectZein-phosphatidylcholine hybrid nanoparticles-
dc.titleA tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer-
dc.typeArticle-
dc.identifier.doi10.1016/j.jddst.2022.103922-
dc.identifier.scopuseid_2-s2.0-85142755370-
dc.identifier.volume79-
dc.identifier.eissn2588-8943-
dc.identifier.isiWOS:000897066800001-
dc.identifier.issnl1773-2247-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats